Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IBM Enriches Health Data Mine With Truven

This article was originally published in Clinica

Executive Summary

IBM says its Watson Health division will boast “the largest and most diverse” repositories of health-related data, after sealing a $2.6bn deal to acquire Truven Health Analytics. The deal, IBM’s fourth healthcare data-related acquisition in less than 12 months, will bring more than 8,500 new clients, including US federal and state government agencies, employers, health plans, hospitals, clinicians and life sciences companies, to Watson Health’s portfolio.

You may also be interested in...

IBM Divests Watson Health Assets To Focus On Cloud And AI Businesses

Investment firm Francisco Partners will acquire IBM’s Watson Health’s data and analytics assets – including Micromedex, MarketScan, and Clinical Development – for an undisclosed price.

IBM Digs Deeper Roots In Medtech, As AdvaMed Builds Digital Footprint

IBM is getting more heavily invested in the medical device industry, announcing two major partnerships this week with diagnostic-maker Illumina and US FDA. The move is part of a larger industry trend of tech firms becoming more active in the medtech sector, and AdvaMed is adjusting to the new context.

Siemens Makes PHM Debut With Partner IBM; Verily, 3M Also Link Arms

Siemens Healthineers will be offering population health management solutions for the first time, as it teams up with IBM Watson Health. Verily and 3M are also joining the PHM partnering wave.


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts